Post-traumatic stress disorder

BetterLife Obtains TD-0148A Receptor Binding Data for IND-Enabling Pharmacology Studies

Retrieved on: 
Wednesday, September 29, 2021
Biotechnology, Patent, G protein-coupled receptor, WHO, LSD, Lists of diseases, Lysergic acid diethylamide, CAGR, ADME, Ion, Depression, NMDA, CSE, Insomnia, Eurofins Scientific, Toxicology, GLOBE, Neuro, Disability, Knowledge, Pharmacology, COVID-19, Post-traumatic stress disorder, IND, Research, Psychiatry, Headache, Drug discovery, Degenerative disease, Safety, Enzyme, Anxiety, Industry, Hallucination, Protein, Disorder, Pharmaceutical industry

The receptor binding data show binding of TD-0148A to neurological receptors which are known to play key roles in neuro-psychiatric disorders.

Key Points: 
  • The receptor binding data show binding of TD-0148A to neurological receptors which are known to play key roles in neuro-psychiatric disorders.
  • Additional preclinical studies are underway to further determine the functional outcome of the TD-0148A binding at these receptors (where possible, outcomes include agonism, antagonism, mixed or no effect).
  • These TD-0148A receptor binding studies are being conducted by Eurofins Discovery at its state-of-the-art facilities at Eurofins Cerep, DiscoverX and Panlabs.
  • "We are pleased to be partnering with Eurofins Discovery and the global Eurofins Discovery team for these TD-0148A primary and safety pharmacology studies as part of TD-0148As IND-enabling preclinical data package.

Freespira Named UCSF Health Awards 2021 Finalist

Retrieved on: 
Tuesday, September 28, 2021
UCSF, Panic disorder, Builder, Instagram, Pharmacy, Carbon dioxide, Naturalism, Hypersensitivity, Veteran, Health, Telehealth, FDA, Patient, Administration, MD, LinkedIn, Highmark, Allegheny Health Network, San Francisco, Twitter, CEO, University, Respiration, The Institute, Silicon, Stanford University, Tuskegee Veterans Administration Medical Center, Technology, Post-traumatic stress disorder, Psychiatry, United States Department of Veterans Affairs, PTSD, Lists of Palestinian rocket attacks on Israel, Capnography, Quality of life, Doctor of Philosophy, General partnership, CO2, Yale School of Medicine, Medical device, Pharmaceutical industry, Health insurance

KIRKLAND, Wash., Sept. 28, 2021 /PRNewswire/ -- Freespira, Inc ., maker of the first FDA-cleared digital therapeutic to significantly reduce or eliminate symptoms of panic disorder and post-traumatic stress disorder (PTSD) in only 28 days, has been named a finalist in the prestigious 2021 UCSF Health Awards , mental and behavioral health category.

Key Points: 
  • KIRKLAND, Wash., Sept. 28, 2021 /PRNewswire/ -- Freespira, Inc ., maker of the first FDA-cleared digital therapeutic to significantly reduce or eliminate symptoms of panic disorder and post-traumatic stress disorder (PTSD) in only 28 days, has been named a finalist in the prestigious 2021 UCSF Health Awards , mental and behavioral health category.
  • "We are honored to be among the finest digital health solutions in the world recognized by the UCSF Health Hub," said Dean Sawyer, CEO of Freespira.
  • The UCSF Health Awards are sponsored by the University of California at San Francisco's Health Hub, an innovation hub and startup studio supporting the next wave of health tech entrepreneurs improving healthcare with technology.
  • UCSF Health Hub connects ideas and companies with the people, expertise, and capital to scale breakthrough healthcare solutions and produces monthly on-campus events operates a company-to mentor-to clinician online matching system called Health Hub Connect and produces the UCSF Digital Health Awards show.

A New Test Could Improve Access to Mental Health Support for Healthcare Professionals Who Are Burned Out From the COVID-19 Pandemic

Retrieved on: 
Tuesday, September 28, 2021
Research, Vaccine, Occupational stress, Depression, Patient, Physician, Hospital, Nursing, Coronavirus, Lists of Palestinian rocket attacks on Israel, Copeptin, Mental health, COVID-19, Post-traumatic stress disorder, ICU, Doctor of Philosophy, Anxiety, Medicine

As COVID-19 cases surge again, this test could play a critical role in helping healthcare professionals on the frontlines of the pandemic to get essential mental health support.

Key Points: 
  • As COVID-19 cases surge again, this test could play a critical role in helping healthcare professionals on the frontlines of the pandemic to get essential mental health support.
  • Making matters worse is the fact that healthcare professionals are also severely overworked because thousands have left the field as a result of the pandemic, causing chronic staffing shortages.
  • It is therefore vital that hospitals improve healthcare professionals' access to mental health support.
  • A blood test for occupational stress could help to achieve this goal by making it easier to identify healthcare professionals who need mental health treatment.

Lobe Sciences Announces Data Demonstrating That Its Combination Therapeutic Candidates are Significantly More Effective Than Monotherapy in mTBI and PTSD

Retrieved on: 
Tuesday, September 28, 2021
News, University of Miami, Trauma, Lobe, Memory, Otorhinolaryngology, Therapy, CGMP, OTC Markets Group, University, CSE, Multimedia, NAC, Physician, Population, Concussion, IP, CEO, THE, Company, Growth, TBI, Mental health, COVID-19, Post-traumatic stress disorder, View, Research, Acetylcysteine, Brain, PTSD, Learning, Forward-looking statement, THIS, Time, Psilocybin, Pharmaceutical industry, Risk management

The rodents treated with the combination of psilocybin and NAC performed statistically significantly better (P

Key Points: 
  • The rodents treated with the combination of psilocybin and NAC performed statistically significantly better (P
  • Philip Young, CEO of Lobe stated, "I am thankful to Dr. Hoffer and his team for their excellent work.
  • Lobe Sciences is a life sciences company focused on psychedelic medicines.
  • This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Redefining Standards, Refining Psychiatry

Retrieved on: 
Tuesday, September 28, 2021
Social media, News, Therapy, Cancer, Neoplasm, Partnership, Chronic pain, Soft-tissue sarcoma, University, LSD, Solution, SMS, Depression, CSE, Pain scale, NNW, MDMA, Dexrazoxane, Program, Prevalence, Awareness, Mental health, Lists of diseases, Disease, DMT, Overload, Post-traumatic stress disorder, Conditional sentence, Anxiety, PFN, Psilocybin, Addiction, Fibromyalgia, GLOBE, Pharmaceutical industry

Psychedelics could redefine standards of care for chronic diseases and reshape psychiatry, including counseling practices, among other things.

Key Points: 
  • Psychedelics could redefine standards of care for chronic diseases and reshape psychiatry, including counseling practices, among other things.
  • Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) is leading this next wave of psychedelic drug development beyond mental health into chronic pain and eating disorders as the company advances its clinical programs.
  • Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and safety profiles for the treatment of rare and other diseases with unmet medical needs.
  • In addition to its PFN program, Tryp is developing TRP-1001, an oral formulation of razoxane for the treatment of soft-tissue sarcoma.

BetterLife Files Patent for TD-0148A for Treatment of Cluster Headaches and Related Disorders

Retrieved on: 
Monday, September 27, 2021
GMP, Biotechnology, Patent, WHO, LSD, Lists of diseases, CAGR, Depression, CSE, Migraine, Insomnia, Neuro, Disability, CEO, Pharmacology, COVID-19, Post-traumatic stress disorder, IND, Headache, Neuropathic pain, PTSD, Degenerative disease, Anxiety, Industry, Hallucination, GLOBE, Disorder, Pharmaceutical industry

BetterLife is developing one of the new compositions of 2-bromo-LSD (TD-0148A) covered by its newly filed provisional patent application.

Key Points: 
  • BetterLife is developing one of the new compositions of 2-bromo-LSD (TD-0148A) covered by its newly filed provisional patent application.
  • BetterLife is already in advanced stages of GMP manufacturing TD-0148A and initiated the necessary preclinical IND-enabling studies for TD-0148A.
  • We are excited to be developing and bringing to market treatments addressing cluster headaches, neuropathic pain and range of mental health conditions, including depression, anxiety and PTSD, and related disorders.
  • BetterLifes pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency and insomnia.

Nikean Foundation announces $5 million gift to create a Psychedelic Psychotherapy Research Centre at Toronto’s University Health Network (UHN)

Retrieved on: 
Monday, September 27, 2021
Psilocybin, GMP, University Health Network, Clinical Care Classification System, Humanity, Curriculum, Research, Interview, Center, Depression, Singhal, Mindfulness, MDMA, Mental health, Good manufacturing practice, Multidisciplinary Association for Psychedelic Studies, Imperial College London, RSVP, MAPS, Principal, Education, Post-traumatic stress disorder, UHN, COVID, RBMedia, Open science, Leadership, PTSD, Telephone, Purging disorder, Addiction, GLOBE, Pharmaceutical industry, Public relations, Medicine

Toronto, Ontario, Sept. 27, 2021 (GLOBE NEWSWIRE) -- The Nikean Foundation (Nikean), a Toronto-based charitable foundation committed to the promotion of research and education in support of the beneficial use of psychedelic medicines, has announced a $5 million transformational gift today in support of psychedelic psychotherapy at the University Health Network (UHN).

Key Points: 
  • Toronto, Ontario, Sept. 27, 2021 (GLOBE NEWSWIRE) -- The Nikean Foundation (Nikean), a Toronto-based charitable foundation committed to the promotion of research and education in support of the beneficial use of psychedelic medicines, has announced a $5 million transformational gift today in support of psychedelic psychotherapy at the University Health Network (UHN).
  • The gift is the largest ever donation in support of psychedelic science and research in Canada.
  • By accepting this gift, UHN is sending a powerful message that Canada is serious about psychedelic research and tackling the existential mental health crisis affecting the masses.
  • Affiliated with UHNs Centre for Mental Health, the new Nikean Psychedelic Psychotherapy Research Centre will anchor Canadas thriving psychedelic innovation and academic research hub, leading to revolutionary advances in how Canada treats mental illness and end-of-life distress.

MINDCURE Launches "Desire Project" To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy

Retrieved on: 
Monday, September 27, 2021
Desire, Star Trek: Phase II, News, Post-traumatic stress disorder, Health minister, Trauma, Distress, Man, University, Instagram, Clinical Obstetrics and Gynecology, Desire Projects, Solution, Moses Austin, III, CSE, Professor, MDMA, LinkedIn, Adult, Manifest and latent functions and dysfunctions, Phrase, Twitter, FRA, CEO, Gynaecology, Company, MAPS, Woman, Female, Fear, Obstetrics, Mental health, Social behavior, COVID-19, Hypoactive sexual desire disorder, Psychiatry, Research, PTSD, Laboratory, Psychotherapy, Theology, HSDD, Department, Birth control, Pharmaceutical industry, Risk management

As part of MINDCURE's research and development, this research program will mark the first psychedelic-based treatment program targeted at addressing what is clinically known as Hypoactive Sexual Desire Disorder ("HSDD"), a common sexual disorder characterized by persistent low sexual desire and emotional distress not attributable to an existing medical condition or relationship issue.

Key Points: 
  • As part of MINDCURE's research and development, this research program will mark the first psychedelic-based treatment program targeted at addressing what is clinically known as Hypoactive Sexual Desire Disorder ("HSDD"), a common sexual disorder characterized by persistent low sexual desire and emotional distress not attributable to an existing medical condition or relationship issue.
  • "We know that sexual health contributes to overall wellbeing and that studies relating to HSDD suggest that female desire has deep roots in the mind.
  • "I'm very excited to lead our team and launch a clinical studyfor the treatment of female Hypoactive Sexual Desire Disorder," said Dr. Joel Raskin, Chief Medical Officer, MINDCURE.
  • This is an exciting opportunity to find a potentially more effective and better tolerated treatment for women affected by this disorder."

Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Retrieved on: 
Wednesday, September 22, 2021
Patent, WIPO, OTC, Anxiety, Therapy, Depression, Patient, USPTO, United States Patent and Trademark Office, GLOBE, CEO, Happiness, Company, Mental health, Risk, Technology, Post-traumatic stress disorder, Research, PTSD, Safety, NEO, World Intellectual Property Organization, Psilocybin, Addiction, Pharmaceutical industry

In addition, the Company is pleased to report positive preclinical data supporting the continued development of MYCO-003.

Key Points: 
  • In addition, the Company is pleased to report positive preclinical data supporting the continued development of MYCO-003.
  • This patent pending formulation has the potential to further reduce patient anxiety as compared to pure psilocybin, when used in therapy or medical practice.
  • Mydecine believes these properties will be synergistic and particularly important for the effective treatment of patients with severe PTSD and extreme anxiety disorders.
  • Mydecine Innovations Group is headquartered in Denver, Colorado, USA with international offices in Leiden, Netherlands.

Ketamine One Signs LOI with Veteran Services USA to Open Therapy Center

Retrieved on: 
Tuesday, September 21, 2021
Virtual reality, Health, Trauma, MEDI, OTC, Science, Workforce, Arizona Department of Veterans' Services, USA, LOI, GLOBE, Suicide, Topical steroid withdrawal, Acquisition, Company, Housing, Ketamine, Supportive Services for Veteran Families, Mental health, Post-traumatic stress disorder, Cannabis, Veterans' affairs, PTSD, History, NEO, American Service-Members' Protection Act, Interim, Industry, Pharmaceutical industry, Hospital

Located in the former MetroSouth Medical Center, the Blue Island Therapy Center is being planned to be part of a larger medical complex.

Key Points: 
  • Located in the former MetroSouth Medical Center, the Blue Island Therapy Center is being planned to be part of a larger medical complex.
  • Pursuant to the LOI, Ketamine One will provide ketamine assisted therapy in other properties in the Veteran Services USA portfolio.
  • The Company will be working with Veteran Services USA to identify further clinic locations for Ketamine One to develop within the growing network of Veteran Services USA properties.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.